title: [The course and limitation of medical treatment for benign prostatic hyperplasia].
abstract: To clarify the effects and limitation of medical treatment for benign prostatic hyperplasia (BPH), 2,476 patients with BPH were analyzed in terms of symptoms, objective findings, treatment modality and whether surgery was required during the course of medical treatment. As initial therapy, 1,320 cases (53.3%) were treated with medicine and 783 cases (31.6%) underwent surgery. In the group of patients initially treated with medicine, 264 cases (20.0%) required surgery and most operations were performed within six months from the start of medical treatment. Those who required surgery had a larger prostate and more residual urine than those who continued medical treatment. This tendency was also observed in the patients treated with antiandrogen. Therefore, medical therapy might be inappropriate to treat the patients with more than 50 ml of residual urine or significantly large prostate such as goose egg sized or larger. In conclusion, medical treatment possessed potential usefulness for the management of BPH, however, there seemed to be limitation of the effects of medical treatment.
authors.affiliation: Department of Urology, School of Medicine, Chiba University.
authors.forename: N
authors.initials: N
authors.lastname: Kitagawa
authors.forename: K
authors.initials: K
authors.lastname: Akakura
authors.forename: S
authors.initials: S
authors.lastname: Akimoto
authors.forename: J
authors.initials: J
authors.lastname: Shimazaki
authors.forename: S
authors.initials: S
authors.lastname: Murakami
authors.forename: T
authors.initials: T
authors.lastname: Ishikawa
authors.forename: S
authors.initials: S
authors.lastname: Kataumi
authors.forename: T
authors.initials: T
authors.lastname: Sotoma
authors.forename: H
authors.initials: H
authors.lastname: Takagishi
authors.forename: Y
authors.initials: Y
authors.lastname: Kitamura
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D012189:Retrospective Studies; D014563:Urodynamics
chemical_list: D000726:Androgen Antagonists